Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- To examine wether adjunctive atomoxetine is more effective thank placebo for
neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained
attention, learning and memory, working memory, and executive functioning. To determine
the effect size of atomoxetine on these neuropsychological measures for follow-up
studies.
- To determine if atomoxetine has short-term benefits for improving weight gain and other
metabolic abnormalities associated with antipsychotics.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore